Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2006

01-09-2006 | Article

Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA

Authors: J. A. Bell, E. Volpi, S. Fujita, J. G. Cadenas, B. B. Rasmussen

Published in: Diabetologia | Issue 9/2006

Login to get access

Abstract

Aims/hypothesis

An elevated lipid content within skeletal muscle cells is associated with the development of insulin resistance and type 2 diabetes mellitus. We hypothesised that in subjects with type 2 diabetes muscle malonyl-CoA (an inhibitor of fatty acid oxidation) would be elevated at baseline in comparison with control subjects and in particular during physiological hyperinsulinaemia with hyperglycaemia. Thus, fatty acids taken up by muscle would be shunted away from oxidation and towards storage (non-oxidative disposal).

Materials and methods

Six control subjects and six subjects with type 2 diabetes were studied after an overnight fast and during a hyperinsulinaemic (0.5 mU kg−1 min−1), hyperglycaemic clamp (with concurrent intralipid and heparin infusions) designed to increase muscle malonyl-CoA and inhibit fat oxidation. We used stable isotope methods, femoral arterial and venous catheterisation, and performed muscle biopsies to measure palmitate kinetics across the leg and muscle malonyl-CoA.

Results

Basal muscle malonyl-CoA concentrations were similar in control and type 2 diabetic subjects and increased (p<0.05) in both groups during the clamp (control, 0.14±0.05 to 0.24±0.05 pmol/mg; type 2 diabetes, 0.09±0.01 to 0.20±0.02 pmol/mg). Basal palmitate oxidation across the leg was not different between groups at baseline and decreased in both groups during the clamp (p<0.05). Palmitate uptake and non-oxidative disposal were significantly greater in the type 2 diabetic subjects at baseline and during the clamp (p<0.05).

Conclusions/interpretation

Contrary to our hypothesis, the dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of muscle malonyl-CoA. However, elevated fatty acid uptake in type 2 diabetes may be a key contributing factor to the increase in fatty acids being shunted towards storage within muscle.
Literature
1.
DeFronzo RA (1997) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Netherlands J Med 50:191–197CrossRef
2.
Shah P, Vella A, Basu A et al (2003) Elevated free fatty acids impair glucose metabolism in women: decreased stimulation of muscle glucose uptake and suppression of splanchnic glucose production during combined hyperinsulinemia and hyperglycemia. Diabetes 52:38–42PubMedCrossRef
3.
Boden G, Lebed B, Schatz M, Homko C, Lemieux S (2001) Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50:1612–1617PubMedCrossRef
4.
Itan SI, Ruderman NB, Schmieder F, Boden G (2002) Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51:2005–2011CrossRef
5.
Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD (2004) Splanchnic lipolysis in human obesity [see comment]. J Clin Invest 113:1582–1588PubMed
6.
Basu A, Basu R, Shah P, Vella A, Rizza RA, Jensen MD (2001) Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 280:E1000–E1006PubMed
7.
Goodpaster BH, Theriault R, Watkins SC, Kelley DE (2000) Intramuscular lipid content is increased in obesity and decreased by weight loss. Metab Clin Exp 49:467–472PubMed
8.
Kelley DE, Goodpaster B, Wing RR, Simoneau JA (1999) Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 277:E1130–E1141PubMed
9.
Mandarino LJ, Consoli A, Jain A, Kelley DE (1996) Interaction of carbohydrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM. Am J Physiol 270:E463–E470PubMed
10.
Kelley DE, Goodpaster BH (2001) Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care 24:933–941PubMedCrossRef
11.
Pan DA, Lillioja S, Kriketos AD et al (1997) Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46:983–988PubMedCrossRef
12.
Schmitz-Peiffer C, Browne CL, Oakes ND et al (1997) Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 46:169–178PubMedCrossRef
13.
Cooney GJ, Thompson AL, Furler SM, Ye J, Kraegen EW (2002) Muscle long-chain acyl CoA esters and insulin resistance. Ann N Y Acad Sci 967:196–207PubMedCrossRef
14.
Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE (1997) Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46:1579–1585PubMedCrossRef
15.
Krssak M, Falk Petersen K, Dresner A et al (1999) Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42:113–116 [erratum: Diabetologia 42:386]PubMedCrossRef
16.
Ellis BA, Poynten A, Lowy AJ et al (2000) Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab 279:E554–E560PubMed
17.
18.
McGarry JD (1995) Malonyl-CoA and carnitine palmitoyltransferase I: an expanding partnership. Biochem Soc Trans 23:481–485PubMed
19.
Rasmussen BB, Holmback UC, Volpi E, Morio-Liondore B, Paddon-Jones D, Wolfe RR (2002) Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle [see comment]. J Clin Invest 110:1687–1693PubMed
20.
Ravikumar B, Carey PE, Snaar JE (2005) Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes. Am J Physiol Endocrinol Metab 288:E789–E797PubMedCrossRef
21.
Bonen A, Parolin ML, Steinberg GR et al (2004) Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. FASEB J 18:1144–1146PubMed
22.
Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495PubMedCrossRef
23.
Patterson BW, Zhao G, Elias N, Hachey DL, Klein S (1999) Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment. J Lipid Res 40:2118–2124PubMed
24.
Wolfe RR (1992) Radioactive and stable isotope tracers in biomedicine. Wiley-Liss, New York
25.
Sacchetti M, Saltin B, Osada T, van Hall G (2002) Intramuscular fatty acid metabolism in contracting and non-contracting human skeletal muscle. J Physiol 540:387–395PubMedCrossRef
26.
Frayn KN (1983) Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol Resp Environ Exerc Physiol 55:628–634
27.
Sacchetti M, Saltin B, Olsen D, van Hall G (2004) High triacylglycerol turnover rate in human skeletal muscle. J Physiol 561.3:883–891CrossRef
28.
van Hall G, Bulow J, Sacchetti M, Al Mulla N, Lyngso D, Simonsen L (2002) Regional fat metabolism in human splanchnic and adipose tissues: the effect of exercise. J Physiol 543:1033–1046PubMedCrossRef
29.
Saha AK, Vavvas D, Kurowski TG et al (1997) Malonyl-CoA regulation in skeletal muscle: its link to cell citrate and the glucose-fatty acid cycle. Am J Physiol 272:E641–E648PubMed
30.
Winder WW, Arogyasami J, Elayan IM, Cartmill D (1990) Time course of exercise-induced decline in malonyl-CoA in different muscle types. Am J Physiol 259:E266–E271PubMed
31.
Mills SE, Foster DW, McGarry JD (1983) Interaction of malonyl-CoA and related compounds with mitochondria from different rat tissues. Relationship between ligand binding and inhibition of carnitine palmitoyltransferase I. Biochem J 214:83–91PubMed
32.
Jorfeldt L, Juhlin-Dannfelt A (1978) The influence of ethanol on splanchnic and skeletal muscle metabolism in man. Metab Clin Exp 27:97–106PubMed
33.
Jorfeldt L, Wahren J (1971) Leg blood flow during exercise in man. Clin Sci 41:459–473PubMed
34.
Bavenholm PN, Pigon J, Saha AK, Ruderman NB, Efendic S (2000) Fatty acid oxidation and the regulation of malonyl-CoA in human muscle. Diabetes 49:1078–1083PubMedCrossRef
35.
Bavenholm PN, Kuhl J, Pigon J, Saha AK, Ruderman NB, Efendic S (2003) Insulin resistance in type 2 diabetes: association with truncal obesity, impaired fitness, and atypical malonyl coenzyme A regulation. J Clin Endocrinol Metab 88:82–87 [erratum: J Clin Endocrinol Metab 88:2036]PubMedCrossRef
36.
Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE (1999) Markers of capacity to utilise fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J 13:2051–2060PubMed
37.
Simoneau JA, Kelley DE (1997) Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. J Appl Physiol 83:166–171PubMed
38.
Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944–2950PubMedCrossRef
39.
Kelley DE, Simoneau JA (1994) Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 94:2349–2356PubMedCrossRef
40.
Hulver MW, Berggren JR, Cortright RN et al (2003) Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab 284:E741–E747PubMed
41.
Golay A, Felber JP, Meyer HU, Curchod B, Maeder E, Jequier E (1984) Study on lipid metabolism in obesity diabetes. Metab Clin Exp 33:111–116PubMed
42.
Felber JP, Ferrannini E, Golay A et al (1987) Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 36:1341–1350PubMedCrossRef
43.
Blaak EE, Wagenmakers AJ, Glatz JF et al (2000) Plasma NEFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. Am J Physiol Endocrinol Metab 279:E146–E154PubMed
44.
Mensink M, Blaak EE, van Baak MA, Wagenmakers AJ, Saris WH (2001) Plasma free fatty acid uptake and oxidation are already diminished in subjects at high risk for developing type 2 diabetes. Diabetes 50:2548–2554PubMedCrossRef
Metadata
Title
Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA
Authors
J. A. Bell
E. Volpi
S. Fujita
J. G. Cadenas
B. B. Rasmussen
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0362-9

Other articles of this Issue 9/2006

Diabetologia 9/2006 Go to the issue

Article

Long-term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes

Article

Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular KATP channels

Commentary

Latent autoimmune diabetes in adults (LADA)—more than a name

Article

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

Article

Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n−3 polyunsaturated fatty acids

Research Letter

Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits